Verition Fund Management LLC Boosts Position in Roivant Sciences Ltd. $ROIV

Verition Fund Management LLC boosted its position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 15.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 728,997 shares of the company’s stock after purchasing an additional 99,500 shares during the quarter. Verition Fund Management LLC’s holdings in Roivant Sciences were worth $15,819,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after purchasing an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. boosted its position in Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after purchasing an additional 583 shares in the last quarter. Bessemer Group Inc. raised its holdings in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after acquiring an additional 543 shares during the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in shares of Roivant Sciences in the fourth quarter worth $47,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Citigroup boosted their price target on Roivant Sciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. Finally, Sanford C. Bernstein assumed coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Trading Down 0.0%

Roivant Sciences stock opened at $30.03 on Tuesday. The firm has a market capitalization of $21.60 billion, a P/E ratio of -50.05 and a beta of 1.13. The stock has a fifty day moving average price of $28.99 and a 200 day moving average price of $26.08. Roivant Sciences Ltd. has a 52 week low of $10.70 and a 52 week high of $32.79.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.57. The firm had revenue of $2.52 million during the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same period in the prior year, the firm posted ($0.29) earnings per share. As a group, equities analysts predict that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Matthew Gline sold 289,774 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $29.16, for a total transaction of $8,449,809.84. Following the completion of the sale, the chief executive officer directly owned 16,736,116 shares in the company, valued at $488,025,142.56. This represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Jennifer Humes sold 13,538 shares of the company’s stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total value of $384,073.06. Following the sale, the chief accounting officer owned 84,191 shares of the company’s stock, valued at $2,388,498.67. This represents a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 703,312 shares of company stock worth $20,805,883. 10.80% of the stock is currently owned by insiders.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.